An official website of the United States government
Government Funding Lapse Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.
The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.
Updates regarding government operating status and resumption of normal operations can be found at opm.gov.
Total Eradication following Radiation for the Treatment of Oligometastatic Prostate Cancer, TERPS Study
Trial Status: enrolling by invitation
This phase II trial compares the effect of standard of care treatment to standard of care treatment in combination with stereotactic ablative radiation therapy (SABR) metastasis-directed therapy (MDT) in patients with prostate cancer that has spread from where it first started (primary site) to other places in the body. For patients with metastatic prostate cancer disease recurrence, the established approach is to offer androgen deprivation therapy (ADT) which improves survival but inevitably leads to castration resistance, and can be associated with significant adverse effects. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue.
Inclusion Criteria
Patient must have at least one and up to three asymptomatic metastatic tumor(s) of the bone or soft tissue (with at least one bone metastasis) develop within the past 6-months that are seen on imaging. Up to five lesions are allowed on advanced functional imaging such as fluciclovine (Axumin), choline or prostate-specific membrane antigen (PSMA) positron emission tomography and computerized tomography (PET-CT) scan.
* CT or MRI scan within 6 months of enrollment
* Bone scan within 6 months of enrollment
* Fluciclovine (Axumin), choline, or PSMA PET-CT scan within 6 months of enrollment
(PET-CT scan is reasonable for study entry imaging as an alternative to CT/MRI scan and bone scan)
Histologic confirmation of malignancy (primary or metastatic tumor).
Patient may have had prior systemic therapy and/or ADT associated with treatment within 9-months of enrollment.
Prostate-Specific Antigen (PSA) > 0.5 but <1 00.
Patient must be >= 18 years of age.
Patient must have a life expectancy >= 12 months.
Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status =< 2.
Patient must have the ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria
Castration-resistant prostate cancer (CRPC).
Prior radiation therapy to an overlapping site of a target lesion that would preclude further radiation therapy.
Spinal cord compression or impending spinal cord compression.
Suspected pulmonary and/or liver metastases (greater >10 mm in largest axis).
Patient receiving any other investigational agents.
Inability to receive any form of systemic therapy in the opinion of a treating medical oncologist .
Unable to lie flat during or tolerate PET/MRI, PET/CT or SABR.
Radiographical evidence of cranial metastasis.
Additional locations may be listed on ClinicalTrials.gov for NCT05223803.
I. To assess 2-year failure-free survival (FFS) of men who have oligometastatic prostate cancer with best systemic therapy (BST) + primary prostate radiation (XRT) versus BST+XRT + stereotactic ablative radiation (SABR) metastasis-directed therapy (MDT).
SECONDARY OBJECTIVES:
I. To assess the toxicity of SABR MDT in patients with new (de novo) oligometastatic disease.
II. To assess time to locoregional progression, time to distant progression, time to new metastasis, radiographic progression-free survival and duration of response after randomization to best systemic therapy (BST) and primary prostate radiation (XRT) versus BST, XRT and stereotactic ablative radiation therapy (SABR) metastasis-directed therapy (MDT).
III. To assess quality-of-life following completion of SABR MDT.
CORRELATIVE OBJECTIVES:
I. To enumerate circulating tumor cells (CTC) using EPIC HD-CTC platforms at baseline, 3 month follow-up and 6 month follow-up.
II. To enumerate plasma at baseline and 3 month follow-up
III. To quantitatively sequence T-cell receptor (TCR) repertoires using peripheral blood monocytes and the ImmunoSEQ platform at baseline, 3 month follow-up and 6 month follow-up
IV. To determine frequency of germline DNA repair mutations in the oligometastatic state.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients undergo best systemic therapy (BST) and primary prostate radiation (XRT) on study. Patients also undergo bone scan and computed tomography (CT)/magnetic resonance imaging (MRI) and undergo collection of blood and rectal samples on throughout the trial.
ARM II: Patients undergo BST, XRT, and stereotactic ablative radiation metastasis-directed therapy (SABR MDT) on study. Patients also undergo bone scan and CT/MRI and undergo collection of blood and rectal samples on throughout the trial.
Trial PhasePhase II
Trial Typetreatment
Lead OrganizationUniversity of Maryland/Greenebaum Cancer Center
